Evidence map›Paper›PMID 42035289›Full record

ArticleBioMed research international2026

KDM3B Predicts Expression Signature, Prognosis Value, and Immune Characteristics of Cancers: A Pan-Cancer Analysis.

Liping Zhu, Xiaoyan Peng, Haile Yu, Xiaolu Fan, Zhoujie Ye

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Liping ZhuFujian Children's Hospital (Fujian Branch of Shanghai Children's Medical Center), College of Clinical Medicine for Obstetrics and Gynecology and Pediatrics, Fujian Medical University, Fuzhou, Fujian, China, fjmu.edu.cn.ORCID https://orcid.org/0009-0006-3117-892X
Xiaoyan PengFujian Children's Hospital (Fujian Branch of Shanghai Children's Medical Center), College of Clinical Medicine for Obstetrics and Gynecology and Pediatrics, Fujian Medical University, Fuzhou, Fujian, China, fjmu.edu.cn.ORCID https://orcid.org/0009-0002-1867-4065
Haile YuMedical Research Center, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics and Gynecology and Pediatrics, Fujian Medical University, Fuzhou, Fujian, China, fjmu.edu.cn.ORCID https://orcid.org/0009-0004-2924-9982
Xiaolu FanMedical Research Center, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics and Gynecology and Pediatrics, Fujian Medical University, Fuzhou, Fujian, China, fjmu.edu.cn.ORCID https://orcid.org/0009-0001-1774-399X
Zhoujie YeMedical Research Center, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics and Gynecology and Pediatrics, Fujian Medical University, Fuzhou, Fujian, China, fjmu.edu.cn.ORCID https://orcid.org/0000-0003-2026-9333

Funding

Joint Funds for the Innovation of Science and Technology, Fujian Province 2021Y9184National Natural Science Foundation of China 82000166Natural Science Foundation of Fujian Province 2022J011032Natural Science Foundation of Fujian Province 2022J011063Province-Level Special Subsidy Funds for Health in Fujian Province Fujian Finance Index(2023)830Research Fund Project of Fujian Maternal and Child Health Hospital YCXM20-11
6 · The paper itself

Abstract

Dysregulation of histone modifications contributes to the development of cancer. The loss of methylation on histone H3 and H4 and the loss of acetylation serve as indicators of tumors. Histone demethylase KDM3B, which contains a JmjC domain, plays an important role in tumorigenesis and development by removing H3K9me1/2 methylation. It also has a significant impact on regulating different types of cancer. KDM3B's role in prognosis and tumor formation in cancer has not been thoroughly studied. In this study, we analyzed KDM3B expression data from the TCGA database in a pan-cancer analysis. Our results show that KDM3B is highly expressed in many cancer types and is closely associated with poor prognosis. KDM3B expression is associated with immune checkpoint activities, lymphocyte infiltration, and immune landscape changes, suggesting that KDM3B could be a target for cancer therapy.

Indexed as

Gene Expression Regulation, NeoplasticJumonji Domain-Containing Histone DemethylasesNeoplasmsBiomarkers, TumorHistonesHumansPrognosisBiomarkers, TumorHistonesJumonji Domain-Containing Histone DemethylasesKDM3B protein, humanhistoneimmune checkpoint inhibitorimmune infiltrationKDM3Bpan-cancer

Identifiers

PMID42035289
PMCPMC13110391

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.